This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Portola Pharmaceuticals Announces Upcoming Data Presentations On Andexanet Alfa (PRT4445*) And PRT2070 At 55th American Society Of Hematology (ASH) Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 3, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced two upcoming data presentations at the 55 th American Society of Hematology (ASH) Annual Meeting and Exposition, which is being held in New Orleans from December 7-10. The Company also will webcast an investor briefing during the ASH Annual Meeting.

New data from a Phase 2 proof-of-concept study of andexanet alfa (PRT4445*), Portola's investigational Factor Xa inhibitor antidote, in healthy volunteers who received the Factor Xa inhibitor XARELTO ® (rivaroxaban) will be presented in a poster session. Andexanet alfa has been designated as a breakthrough therapy by the U.S. Food and Drug Administration, and has the potential to be a first-in-class agent that directly reverses the anticoagulant activity of Factor Xa inhibitors in patients with major bleeding or those needing emergency surgery.

Additionally, in vitro data on PRT2070, Portola's oral, dual spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor, will be presented in a poster session. Portola is developing PRT2070 as a treatment for hematologic cancers and is evaluating the agent in a Phase 1/2 proof-of-concept clinical study in patients with non-Hodgkin's lymphoma or chronic lymphocytic leukemia, including those patients who have progressive or relapsed disease, genetically-defined subtypes or acquired mutations.

The abstracts are available at and and were published online in the November 15 supplemental volume of Blood. Details of the poster presentations and investor briefing webcast follow.

Andexanet Alfa
  • Abstract title: Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal of Rivaroxaban-Induced Anticoagulation in Healthy Subjects By Andexanet Alfa (PRT064445), an Antidote for Fxa Inhibitors
  • Poster Presenter: Mark Crowther, M.D., M.Sc., associate chair, Department of Medicine, McMaster University, Hamilton, Ontario
  • Date/Time: Monday, December 9, 6:00-8:00 p.m. Central Time (CT)
  • Session: 332. Antithrombotic Therapy: Poster III
  • Location: Ernest N. Morial Convention Center, Hall E

  • Abstract title: Dual SYK/JAK Inhibition Has a Broader Anti-Tumor Activity in Both ABC and GCB Types of Diffuse Large B Cell Lymphoma
  • Poster Presenter: Y. Lynn Wang, M.D., Ph.D., professor and medical director, Division of Genomic and Molecular Pathology, Department of Pathology, University of Chicago
  • Date/Time: Saturday, December 7, 5:30-7:30 p.m. CTSession: 625. Lymphoma: Pre-Clinical – Chemotherapy and Biologic Agents: Poster I
  • Location: Ernest N. Morial Convention Center, Hall G

Investor Briefing Webcast Details

Portola will host an investor briefing on Monday, December 9, at 2:05 p.m. Central Time (3:05 p.m. Eastern Time) during the ASH Annual Meeting in New Orleans. During the event, Portola's senior management team will provide an update on the Company's recent business progress. A live webcast of the event will be available via the Investor Relations section of the Company's website at A replay will be available on the Company's website for 30 days following the live event.

About Portola Pharmaceuticals, Inc.

Robust thrombosis and hematology pipeline with betrixaban, andexanet alfa and PRT2070

Portola Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics in the areas of thrombosis and hematology.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.85 -3.00%
FB $116.83 7.30%
GOOG $691.17 -2.10%
TSLA $247.62 -1.50%
YHOO $36.60 -0.95%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,074.51 -20.64 -0.99%
NASDAQ 4,805.6670 -57.4740 -1.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs